Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Dec 2012

Weickhardt Andrew J, Scheier Benjamin, Burke Joseph Malachy, Gan Gregory, Lu Xian, Bunn Paul A, Aisner Dara L, Gaspar Laurie E, Kavanagh Brian D, Doebele Robert C, Camidge D Ross

Abstract excerpt

INTRODUCTION: Many patients with oncogene-driven non-small-cell lung cancer (NSCLC) treated with tyrosine kinase inhibitors experience limited sites of disease progression. This study investigated retrospectively the benefits of local ablative therapy (LAT) to central nervous system (CNS) and/or limited systemic disease progression and continuation of crizotinib or erlotinib in patients with metastatic ALK gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Catheter Ablation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Crizotinib

Share to Erlotinib Hydrochloride

Share to Pyrazoles

Share to Pyridines

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 23154552
DOI: 10.1097/JTO.0b013e3182745948
PMCID: PMC3506112

Genes

ALK
EGFR
LAT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.PMID 23154552Read ↗

Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation.Semantic proximity Read ↗

Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?Semantic proximity Read ↗

Local ablative radiotherapy on oligo-progression while continued on epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer patients: A longer cohort.Semantic proximity Read ↗

Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.Semantic proximity Read ↗

Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations.Semantic proximity Read ↗

Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.Semantic proximity Read ↗

Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies.Semantic proximity Read ↗

Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.Semantic proximity Read ↗

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.Semantic proximity Read ↗

Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.